News Column

Neovasc earns a spot in 2014 PROFIT 500 List

June 23, 2014

By a News Reporter-Staff News Editor at Clinical Trials Week -- Neovasc Inc. ("Neovasc" or the

"Company") (NASDAQ: NVCN) (TSXV: NVC) is pleased to announce that it has been listed in the 2014 PROFIT 500 as one of Canada's fastest growing companies. Having achieved an average revenue growth of approximately 50% year over year since its inception in 2008, Neovasc attributes its success to its strong customer relationships, attention to operational excellence, and dedication to furthering advances in cardiovascular device technology (see also Neovasc Inc.).

"We appreciate this recognition of our success and share the honour with each of our employees, customers, shareholders, and industry partners and offer our congratulations to all those named in this year's PROFIT 500," states Alexei Marko, CEO at Neovasc.

In addition to recently announcing strong clinical trial results for its

Reducer™ product for the treatment of refractory angina, the Company's

Tiara™ valve is now widely recognized as a leading program for transcatheter mitral valve replacement. Neovasc's tissue development, supply and manufacturing business provides services to a range of customers around the world as a trusted provider of biological tissue and cardiovascular device contract manufacturing services.

Published annually, the PROFIT 500 lists and profiles Canada's Fastest-Growing Companies by five-year revenue growth and gives entrepreneurs and their businesses the recognition they deserve for their achievements and contributions to Canada.

Keywords for this news article include: Cardiology, Neovasc Inc, Cardio Device, Cardiovascular, Medical Devices.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Clinical Trials Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters